Pneumonia is the most common hospital-acquired (nosocomial) infection. Hospital-acquired ventilator-associated pneumonia (VAP) is one of the most frequent infections seen in ICUs. VAP develops in patients who have been on mechanical ventilation for more than 48 hours. It is caused by microbial colonization of the respiratory tract and lungs, often due to prolonged intubation, inadequate oral hygiene and/or aspiration of upper respiratory tract secretions.
Despite reports of dramatic decreases in ventilator-associated pneumonia rates over the past two decades, 5–10% of ventilated patients continue to be treated for VAP and/or ventilator-associated events (VAE). Complications of VAP include respiratory failure, acute respiratory distress syndrome, sepsis, multidrug-resistant infections and ventilator dependence. The result is prolonged ICU stays, increased healthcare costs and increased mortality, making prevention strategies essential in reducing its incidence.
The following article presents a comparison of primary prevention strategies and appropriate supplemental interventions for VAP provided by the Society for Healthcare Epidemiology of America (SHEA) in 2022 and the International Society of Infectious Disease (ISID) in 2024. This evidence-based approach aims to reduce rates of VAP, shorten the duration of mechanical ventilation, decrease the length of hospital stays and lower mortality rates.
Titles of Comparison:
| Titles | Prevention of Ventilator-Associated Pneumonia, Ventilator-Associated Events, and Nonventilator Hospital-Acquired Pneumonia in Acute Care Hospitals - 2022 | Preventing Ventilator-Associated Pneumonia - 2024 |
|---|---|---|
| Society | Society for Healthcare Epidemiology of America (SHEA) | International Society for Infectious Diseases (ISID) |
| Publication Date | May 2022 | November 2024 |
| Objective | Provide practical recommendations to assist acute care hospitals to prioritize and implement strategies to prevent VAP in adults, children and neonates | Provide recommendations on prevention of hospital-acquired VAP in adults, while addressing risk factors in high-income and low- to middle-income countries |
| Primary Audience | Healthcare Professionals, Infection Control Teams and Hospital Epidemiologists | Nurse, Nurse Practitioners, Physicians and Physician Assistants |
| Methodology | Evidence-based review and expert consensus | Evidence-based review and expert consensus |
| Graded Strength of Recommendations | No | No |
| Graded Level of Evidence | Yes | Yes |
| Systematic Review | Yes | Yes |
| Literature Review | Yes | Yes |
| Full Text | Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals | Preventing Ventilator-Associated Pneumonia |
| Guideline Central | Summary | Overview |
Definition & Diagnosis
- Definition of VAP
- ISID (2024): Defines VAP as pneumonia occurring 48 hours or more after endotracheal intubation.
- SHEA (2022): Uses the same definition but emphasizes that VAP occurs in mechanically ventilated patients.
- Diagnosis of VAP
- ISID (2024): Recommends a combination of clinical, radiological, and microbiological criteria.
- SHEA (2022): Suggests clinical criteria, including new infiltrates on chest radiographs and purulent secretions.
- Microbiological Diagnosis
- ISID: Emphasizes avoiding overuse of cultures and recommends non-invasive methods when possible.
- SHEA: Supports selective use of cultures but stresses the importance of identifying causative pathogens.
Treatment of VAP
- Empiric Antibiotic Therapy
- ISID: Recommends broad-spectrum antibiotics initially, with de-escalation based on culture results.
- SHEA: Supports a similar approach but emphasizes narrowing therapy to specific pathogens based on culture results.
- Duration of Antibiotic Therapy
- ISID: Suggests a shorter antibiotic course (7-8 days) based on patient response.
- SHEA: Aligns with ISID but stresses an individualized approach.
- Use of Biomarkers
- Both ISID and SHEA: Recommend biomarkers (e.g., procalcitonin) to guide antibiotic duration, though SHEA urges caution in interpretation.
- Management of Multidrug-Resistant (MDR) Pathogens
- Both guidelines recommend timely identification and treatment of MDR organisms, with rapid targeted therapy.
Prevention Strategies
- Both SHEA and ISID prioritize infection control practices but vary in their emphasis on specific interventions.
Primary Prevention Strategies
| Strategy | SHEA (2022) | ISID (2024) |
|---|---|---|
| Avoid intubation and reintubation | Strong recommendation | Strong recommendation |
| Minimize sedation | Strongly recommended | Conditionally recommended |
| Elevate head of bed (30-45 degrees) | Suggested recommendation | Suggested recommendation |
| Oral care (tooth brushing, no chlorhexidine) | Conditional recommendation | Conditional recommendation |
| Early enteral vs. parenteral nutrition | Strong recommendation | Strong recommendation |
| Use of continuous cuff pressure control | Not specifically addressed | Suggested recommendation |
Supplementary Interventions
| Intervention | SHEA (2022) | ISID (2024) |
|---|---|---|
| Selective oral or digestive decontamination | Strong recommendation in low AMR settings | Strong recommendation in low AMR settings |
| Endotracheal tubes with subglottic secretion drainage | Conditional recommendation | Conditional recommendation |
| Early tracheostomy | Conditional recommendation | Conditional recommendation |
| Post-pyloric feeding for high aspiration risk | Conditional recommendation | Conditional recommendation |
Interventions NOT Recommended
| Intervention | SHEA (2022) | ISID (2024) |
|---|---|---|
| Oral care with chlorhexidine | Conditional recommendation | Conditional recommendation |
| Use of probiotics | Conditional recommendation | Conditional recommendation |
| Silver-coated endotracheal tubes | Not recommended | Pending resolution |
| Frequent cuff pressure monitoring | Not recommended | Not addressed |
Key Differences and Similarities
- Differences:
- Microbiological Diagnosis: ISID is more cautious about over-relying on cultures and suggests non-invasive testing, while SHEA emphasizes identifying pathogens through cultures.
- Empiric Therapy: ISID stresses de-escalation of antibiotics, while SHEA encourages early narrowing to identified pathogens.
- Prevention Focus: SHEA provides more detailed interventions such as oral care and head-of-bed elevation, while ISID broadly emphasizes infection control practices.
- Sedation Minimization: SHEA strongly recommends it, whereas ISID provides a conditional recommendation.
- Similarities:
- Both support short antibiotic courses (7-8 days) when clinically appropriate.
- Both recommend broad-spectrum empiric antibiotics followed by de-escalation.
- Both emphasize prevention strategies and highlight multimodal approaches.
Both the 2024 ISID and 2022 SHEA guidelines offer evidence-based recommendations that aim to optimize VAP diagnosis, treatment, and prevention strategies. And while they agree on core principles, they differ in diagnostic approaches, antibiotic de-escalation strategies, and specific prevention interventions. But ultimately, healthcare providers must consider both sets of guidelines in the context of their local clinical environment, resistance patterns, and individual patient factors. By doing so, they can optimize the management of VAP, improve patient outcomes, and help mitigate the growing threat of antimicrobial resistance.
Make sure to sign up for guideline alerts to stay up to date on all future side-by-side blogs and let us know if there is a topic you’d like to see compared on our next article!
Copyright © 2025 Guideline Central, All Rights Reserved.